Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum.

S. S. Robey-Cafferty, A. K. el-Naggar, David Grignon, K. R. Cleary, J. Y. Ro

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Stage B adenocarcinomas of colon (61 carcinomas) and rectum (44 carcinomas) were retrospectively reviewed in order to define prognostic indicators and to determine if they are different for tumors arising at the two sites. Parameters evaluated included the substage of the tumor, histologic grade, presence of vascular/lymphatic invasion, residual adenoma or extracellular mucin, and tumor cell DNA content as determined by flow cytometry of paraffin-embedded tissues. Five-year survival was 81.0% for patients with colonic and 87.5% for those with rectal tumors. DNA ploidy was a significant predictor of overall and disease-free survival in patients with rectal adenocarcinomas (improved survival for those with diploid tumors) but not in those with colonic tumors and not in the two groups combined. The degree of differentiation of the tumor was prognostically significant in the colonic group and for the groups combined but not in the rectal group. There was a trend toward better survival in substage B1 tumors, as compared with substages B2 and B3, particularly in rectal neoplasms. Other histologic parameters did not predict survival. We conclude that the prognostic indicators in colonic adenocarcinoma seem to differ from those of adenocarcinoma arising in the rectum and that DNA ploidy has a significant impact upon outcome in stage B rectal adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)261-266
Number of pages6
JournalModern Pathology
Volume3
Issue number3
StatePublished - May 1990
Externally publishedYes

Fingerprint

Ploidies
Rectum
Colon
Adenocarcinoma
Survival
DNA
Neoplasms
Rectal Neoplasms
Carcinoma
Mucins
Diploidy
Adenoma
Paraffin
Disease-Free Survival
Blood Vessels
Flow Cytometry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Robey-Cafferty, S. S., el-Naggar, A. K., Grignon, D., Cleary, K. R., & Ro, J. Y. (1990). Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum. Modern Pathology, 3(3), 261-266.

Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum. / Robey-Cafferty, S. S.; el-Naggar, A. K.; Grignon, David; Cleary, K. R.; Ro, J. Y.

In: Modern Pathology, Vol. 3, No. 3, 05.1990, p. 261-266.

Research output: Contribution to journalArticle

Robey-Cafferty, SS, el-Naggar, AK, Grignon, D, Cleary, KR & Ro, JY 1990, 'Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum.', Modern Pathology, vol. 3, no. 3, pp. 261-266.
Robey-Cafferty, S. S. ; el-Naggar, A. K. ; Grignon, David ; Cleary, K. R. ; Ro, J. Y. / Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum. In: Modern Pathology. 1990 ; Vol. 3, No. 3. pp. 261-266.
@article{8949e1e773784de69d449e6673396c40,
title = "Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum.",
abstract = "Stage B adenocarcinomas of colon (61 carcinomas) and rectum (44 carcinomas) were retrospectively reviewed in order to define prognostic indicators and to determine if they are different for tumors arising at the two sites. Parameters evaluated included the substage of the tumor, histologic grade, presence of vascular/lymphatic invasion, residual adenoma or extracellular mucin, and tumor cell DNA content as determined by flow cytometry of paraffin-embedded tissues. Five-year survival was 81.0{\%} for patients with colonic and 87.5{\%} for those with rectal tumors. DNA ploidy was a significant predictor of overall and disease-free survival in patients with rectal adenocarcinomas (improved survival for those with diploid tumors) but not in those with colonic tumors and not in the two groups combined. The degree of differentiation of the tumor was prognostically significant in the colonic group and for the groups combined but not in the rectal group. There was a trend toward better survival in substage B1 tumors, as compared with substages B2 and B3, particularly in rectal neoplasms. Other histologic parameters did not predict survival. We conclude that the prognostic indicators in colonic adenocarcinoma seem to differ from those of adenocarcinoma arising in the rectum and that DNA ploidy has a significant impact upon outcome in stage B rectal adenocarcinomas.",
author = "Robey-Cafferty, {S. S.} and el-Naggar, {A. K.} and David Grignon and Cleary, {K. R.} and Ro, {J. Y.}",
year = "1990",
month = "5",
language = "English (US)",
volume = "3",
pages = "261--266",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum.

AU - Robey-Cafferty, S. S.

AU - el-Naggar, A. K.

AU - Grignon, David

AU - Cleary, K. R.

AU - Ro, J. Y.

PY - 1990/5

Y1 - 1990/5

N2 - Stage B adenocarcinomas of colon (61 carcinomas) and rectum (44 carcinomas) were retrospectively reviewed in order to define prognostic indicators and to determine if they are different for tumors arising at the two sites. Parameters evaluated included the substage of the tumor, histologic grade, presence of vascular/lymphatic invasion, residual adenoma or extracellular mucin, and tumor cell DNA content as determined by flow cytometry of paraffin-embedded tissues. Five-year survival was 81.0% for patients with colonic and 87.5% for those with rectal tumors. DNA ploidy was a significant predictor of overall and disease-free survival in patients with rectal adenocarcinomas (improved survival for those with diploid tumors) but not in those with colonic tumors and not in the two groups combined. The degree of differentiation of the tumor was prognostically significant in the colonic group and for the groups combined but not in the rectal group. There was a trend toward better survival in substage B1 tumors, as compared with substages B2 and B3, particularly in rectal neoplasms. Other histologic parameters did not predict survival. We conclude that the prognostic indicators in colonic adenocarcinoma seem to differ from those of adenocarcinoma arising in the rectum and that DNA ploidy has a significant impact upon outcome in stage B rectal adenocarcinomas.

AB - Stage B adenocarcinomas of colon (61 carcinomas) and rectum (44 carcinomas) were retrospectively reviewed in order to define prognostic indicators and to determine if they are different for tumors arising at the two sites. Parameters evaluated included the substage of the tumor, histologic grade, presence of vascular/lymphatic invasion, residual adenoma or extracellular mucin, and tumor cell DNA content as determined by flow cytometry of paraffin-embedded tissues. Five-year survival was 81.0% for patients with colonic and 87.5% for those with rectal tumors. DNA ploidy was a significant predictor of overall and disease-free survival in patients with rectal adenocarcinomas (improved survival for those with diploid tumors) but not in those with colonic tumors and not in the two groups combined. The degree of differentiation of the tumor was prognostically significant in the colonic group and for the groups combined but not in the rectal group. There was a trend toward better survival in substage B1 tumors, as compared with substages B2 and B3, particularly in rectal neoplasms. Other histologic parameters did not predict survival. We conclude that the prognostic indicators in colonic adenocarcinoma seem to differ from those of adenocarcinoma arising in the rectum and that DNA ploidy has a significant impact upon outcome in stage B rectal adenocarcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0025425144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025425144&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 261

EP - 266

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -